Author Archives: 瑶 翟

PSMA: A Key Target for Radiotherapy and Diagnosis in Prostate Cancer

Prostate-specific membrane antigen (PSMA) is a pivotal molecular target in the treatment and diagnosis of prostate cancer (PCa). Over the past two decades, extensive research has illuminated its unique molecular characteristics, paving the way for advanced diagnostic and therapeutic approaches. PSMA-targeted imaging techniques, particularly positron emission tomography (PET) radiotracers, have demonstrated exceptional sensitivity in detecting […]

Blog 2024-12-13

GDF-15: An Emerging Target for Obesity Treatment

Recent statistics reveal a growing interest in targeting GDF-15 for therapeutic interventions. Currently, there are several drugs targeting GDF-15, with some facing challenges or discontinuation. Of the remaining candidates, many are in early development stages, including preclinical and clinical trials. Specifically, a few drugs have advanced to Phase 1 and Phase 2 clinical trials. These […]

Blog 2024-11-13

Advances in Targeting B-Cell Maturation Antigen (BCMA) for Non-Invasive Imaging and Therapy in Multiple Myeloma

Recent advancements in the field of nuclear medicine have highlighted the significance of B-Cell Maturation Antigen (BCMA) as a pivotal target for the diagnosis and treatment of Multiple Myeloma (MM). In a groundbreaking study published in the European Journal of Nuclear Medicine and Molecular Imaging, a collaborative effort by the molecular imaging team at the First Affiliated Hospital of Jinan University and the Chinese Academy of Medical Sciences has demonstrated the efficacy of the radiolabeled antibody [89Zr]Zr-DFO-BCMAh230430 in non-invasive PET imaging of MM. This research represents a significant step forward in the development of specific immuno-PET probes targeting BCMA, which is highly expressed in malignant plasma cells.

Blog 2024-10-24

The glucagon receptor (GCGR)：A Key Target in Glucose Metabolism

On June 25, 2024, at the 2024 American Diabetes Association (ADA) Scientific Sessions, Suzhou Innovent Biologics and Eli Lilly announced the results of a Phase 3 clinical trialfor the GLP-1R x GCGR dual agonist, Mazdutide. This marks the first Phase 3 clinical trial (GLORY-1) in overweight or obese adults in China。The study’s primary results and exploratory endpoints of liver fat content were disclosed, showing that Mazdutide acts as a dual agonist for both GLP-1R and GCGR. It reduces body weight by suppressing appetite and delaying gastric emptying through GLP-1R activation, while enhancing weight loss efficacy by increasing energy expenditure via GCGR activation. Notably, Mazdutide uniquely promotes fatty acid oxidation and lipolysis in the liver through GCGR activation, thereby improving liver fat metabolism. As GCGR plays a crucial role in glucose metabolism, it has become a hot target in the development of diabetes and weight loss drugs.Let’s delve into the role of  the Glucagon Receptor (GCGR).

Blog , 2024-08-29